Ainos Inc (AIMD)

Ainos, Inc.'s stock has traded between $1.26 and $4.50 over the past 52 weeks. The company was reclassified to the Technology sector in October 2025. Ainos secured seven new patents for its AI Nose digital olfaction platform across Europe, Germany, Taiwan, and China in September 2025. Strategic partnerships and deployments include collaborations with NEXCOM International Co., Ltd. and Topco Scientific. Ainos formed ScentAI Inc., a software subsidiary, in December 2025. A three-year distribution agreement with Trusval Technology was signed in January 2026. The company reported full-year 2025 financial results in March 2026, highlighting revenue growth and a positive gross margin, but the stock price has been falling.

There is no explicit mention of demand seasonality for Ainos, Inc.'s products and services. Demand is driven by ongoing operational needs, technological adoption, and health monitoring requirements rather than seasonal fluctuations. The company emphasizes continuous integration of its technologies into various sectors.

Ainos, Inc. is a dual-platform technology company focused on AI-based "smelltech" and immune therapeutics. It aims to commercialize its AI Nose scent digitization platform, applying it across sectors like semiconductor manufacturing and healthcare. The company also develops VELDONA, a low-dose oral interferon program targeting various diseases, and offers medtech solutions like COVID-19 Antigen Rapid Test Kits.

Ainos, Inc. was initially based in San Diego, California, but relocated its U.S. headquarters to Houston, Texas, in early 2026. It also has a presence in Taiwan, with an office in Zhubei City. The AI Nose platform has expanded into Asia, with deployments in industrial, semiconductor, automation, and robotics sectors. Clinical trials for VELDONA and Ainos Flora are underway in Taiwan.

Ainos, Inc.'s brand reputation has been positively influenced by its advancements in AI and biotech. The expansion of Smell AI deployments, strategic partnerships with entities like MacKay Memorial Hospital and Topco Scientific, positive third-party research, and patent achievements have contributed to its reputation. Despite a stock price decline, the company's reputation in technological innovation and commercialization efforts remains strong.

Ainos, Inc. has a mix of institutional and individual owners. As of May 1, 2026, there are 20 institutional owners and shareholders holding a total of 248,546 shares, including Renaissance Technologies Llc and Vanguard Group Inc. Taiwan Carbon Nano Technology Corp is a significant shareholder, and Ting Chuan Lee increased his beneficial ownership to 10.98% of the common stock in April 2026.